The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: Functional characterization and expression/penetrance studies

25Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Hereditary medullary thyroid carcinoma (MTC) is caused by germ-line gain of function mutations in the RET proto-oncogene, and a phenotypic variability among carriers of the same mutation has been reported. We recently observed this phenomenon in a large familial MTC (FMTC) family carrying the RET-S891A mutation. Among genetic modifiers affecting RET-driven MTC, a role has been hypothesized for RET-G691S non-synonymous polymorphism, though the issue remains controversial. Aim of this study was to define the in vitro contribution of RET-G691S to the oncogenic potential of the RET-S891A, previously shown to harbour low transforming activity. Methods: The RET-S891A and RET-G691S/S891A mutants were generated by site-directed mutagenesis, transiently transfected in HEK293T cells and stably expressed in NIH3T3 cells. Their oncogenic potential was defined by assessing the migration ability by wound healing assay and the anchorage-independent growth by soft agar assay in NIH3T3 cells stably expressing either the single or the double mutants. Two RET-S891A families were characterised for the presence of RET-G691S. Results: The functional studies demonstrated that RET-G691S/S891A double mutant displays a higher oncogenic potential than RET-S891A single mutant, assessed by focus formation and migration ability. Moreover, among the 25 RET-S891A carriers, a trend towards an earlier age of diagnosis was found in the MTC patients harboring RET-S891A in association with RET-G691S. Conclusions: We demonstrate that the RET-G691S non-synonymous polymorphism enhances in vitro the oncogenic activity of RET-S891A. Moreover, an effect on the phenotype was observed in the RET-G691S/S891A patients, thus suggesting that the analysis of this polymorphism could contribute to the decision on the more appropriate clinical and follow-up management.

References Powered by Scopus

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

1747Citations
N/AReaders
Get full text

Medullary thyroid cancer: management guidelines of the American Thyroid Association.

1149Citations
N/AReaders
Get full text

RET tyrosine kinase signaling in development and cancer

387Citations
N/AReaders
Get full text

Cited by Powered by Scopus

State-of-the-art strategies for targeting RET-dependent cancers

217Citations
N/AReaders
Get full text

miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma

83Citations
N/AReaders
Get full text

Multiple endocrine neoplasia type 2: A review

72Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Colombo, C., Minna, E., Rizzetti, M. G., Romeo, P., Lecis, D., Persani, L., … Borrello, M. G. (2015). The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: Functional characterization and expression/penetrance studies. Orphanet Journal of Rare Diseases, 10(1). https://doi.org/10.1186/s13023-015-0231-z

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 14

61%

Researcher 5

22%

Professor / Associate Prof. 4

17%

Readers' Discipline

Tooltip

Medicine and Dentistry 16

62%

Biochemistry, Genetics and Molecular Bi... 8

31%

Agricultural and Biological Sciences 2

8%

Save time finding and organizing research with Mendeley

Sign up for free